The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
Primary Purpose
Re-stenosis, Cirrhosis of the Liver
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
ZES
BMS
Sponsored by
About this trial
This is an interventional diagnostic trial for Re-stenosis focused on measuring LTX Study
Eligibility Criteria
Inclusion Criteria:
- male and female patients with a severe dysfunction of liver
- patient is planned a coronary stent implantation
- adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel
- written informed consent prior to study participation
Exclusion Criteria:
- younger than 18 years
- pregnancy and breast-feeding
- acute cardiac syndrome
- contraindication against an intracardiac catheter
- persons in dependence from the sponsor or working with the sponsor
- participation in a parallel interventional clinical trial
- patient has been committed to an institution by legal or regulatory order
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
coated stent
uncoated stent
Arm Description
the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
Outcomes
Primary Outcome Measures
the ideal stent (coated stent or uncoated stent)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02809248
Brief Title
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
Official Title
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX-Stent Study)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Withdrawn
Why Stopped
Due to the small number of patients, none could be included in the study.
Study Start Date
July 2016 (undefined)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RWTH Aachen University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the study is to choose an optimal stent and to get further knowledge about the mechanisms of the engraftment of a stent.
The occurrence of a hyperplasia of neointima can be minimized by application of a coated stent and a concurrent safety four weekly dual thrombocytes therapy
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Re-stenosis, Cirrhosis of the Liver
Keywords
LTX Study
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
coated stent
Arm Type
Active Comparator
Arm Description
the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
Arm Title
uncoated stent
Arm Type
Active Comparator
Arm Description
the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
Intervention Type
Device
Intervention Name(s)
ZES
Intervention Description
stent implantation (zotarolimus eluting stent)
Intervention Type
Device
Intervention Name(s)
BMS
Intervention Description
stent implantation (bare metal stent)
Primary Outcome Measure Information:
Title
the ideal stent (coated stent or uncoated stent)
Time Frame
5 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
male and female patients with a severe dysfunction of liver
patient is planned a coronary stent implantation
adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel
written informed consent prior to study participation
Exclusion Criteria:
younger than 18 years
pregnancy and breast-feeding
acute cardiac syndrome
contraindication against an intracardiac catheter
persons in dependence from the sponsor or working with the sponsor
participation in a parallel interventional clinical trial
patient has been committed to an institution by legal or regulatory order
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Becker, MD
Organizational Affiliation
Uniklinik RWTH Aachen, Med. Klinik I
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)
We'll reach out to this number within 24 hrs